Cargando…
Safety of Semaglutide
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety c...
Autores principales: | Smits, Mark M., Van Raalte, Daniël H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294388/ https://www.ncbi.nlm.nih.gov/pubmed/34305810 http://dx.doi.org/10.3389/fendo.2021.645563 |
Ejemplares similares
-
Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021) -
The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019) -
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021) -
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021) -
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)